These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17146166)

  • 1. A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab.
    Tsutani Y; Ohsumi S; Aogi K; Taira N; Kataoka M; Hamamoto Y; Nishimura R; Takashima S
    Breast Cancer; 2006; 13(4):374-7. PubMed ID: 17146166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report.
    Takahashi M; Inoue K; Goto R; Tamura M; Taguchi K; Takahashi H; Suzuki H; Katsushige K; Ogita M
    Breast Cancer; 2003; 10(2):170-4. PubMed ID: 12736573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.
    Tubbs RR; Pettay JD; Roche PC; Stoler MH; Jenkins RB; Grogan TM
    J Clin Oncol; 2001 May; 19(10):2714-21. PubMed ID: 11352964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.
    Simon R; Nocito A; Hübscher T; Bucher C; Torhorst J; Schraml P; Bubendorf L; Mihatsch MM; Moch H; Wilber K; Schötzau A; Kononen J; Sauter G
    J Natl Cancer Inst; 2001 Aug; 93(15):1141-6. PubMed ID: 11481385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
    Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S
    Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
    Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
    Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
    Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ; Press M
    J Clin Oncol; 2002 Feb; 20(3):719-26. PubMed ID: 11821453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A long survival of a patient with poor performance status who suffered from advanced right breast cancer with multiple lung metastases controlled by trastuzumab as a key drug].
    Fujikawa T; Mukai K; Tanaka A; Abe T; Yoshimoto Y; Tada S; Maekawa H; Shimoike N; Tanaka H; Kawashima T; Yokota T
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):1009-12. PubMed ID: 22705704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
    Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
    World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2 status determination in breast carcinomas. A practical approach.
    García-Caballero T; Menéndez MD; Vázquez-Boquete A; Gallego R; Forteza J; Fraga M
    Histol Histopathol; 2006 Mar; 21(3):227-36. PubMed ID: 16372244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy.
    Maciá Escalante S; Rodríguez Lescure A; Pons Sanz V; Martínez Banaclocha N; Guillén Ponce C; Carrato Mena A
    Clin Transl Oncol; 2006 Oct; 8(10):761-3. PubMed ID: 17074677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody.
    Ohta M; Tokuda Y; Suzuki Y; Kubota M; Watanabe T; Fujii H; Sasaki Y; Niwa T; Makuuchi H; Tajima T
    Jpn J Clin Oncol; 2001 Nov; 31(11):553-6. PubMed ID: 11773264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis of HER2 gene amplification in breast carcinoma].
    Couturier J; Vincent-Salomon A; Mathieu MC; Valent A; Bernheim A
    Pathol Biol (Paris); 2008 Sep; 56(6):375-9. PubMed ID: 18456424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type.
    Ninomiya K; Ohi S; Tabei I; Jin S; Tachibana T; Yamashita S; Yanaga K; Hashimoto H
    Hum Cell; 2007 Aug; 20(3):85-90. PubMed ID: 17645728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
    Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
    Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.